Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2011

Risk factors associated with Hepatitis C among female substance
users enrolled in communitybased HIV prevention studies
Diana Nurutdinova
Washington University School of Medicine in St. Louis

Arbi B. Abdallah
Washington University School of Medicine in St. Louis

Susan Bradford
Washington University School of Medicine in St. Louis

Catina C. O'Leary
Washington University School of Medicine in St. Louis

Linda B. Cottler
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Part of the Medicine and Health Sciences Commons

Recommended Citation
Nurutdinova, Diana; Abdallah, Arbi B.; Bradford, Susan; O'Leary, Catina C.; and Cottler, Linda B., ,"Risk
factors associated with Hepatitis C among female substance users enrolled in communitybased HIV
prevention studies." BMC Research Notes. 4,. 126. (2011).
https://digitalcommons.wustl.edu/open_access_pubs/64

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Nurutdinova et al. BMC Research Notes 2011, 4:126
http://www.biomedcentral.com/1756-0500/4/126

SHORT REPORT

Open Access

Risk factors associated with Hepatitis C among
female substance users enrolled in communitybased HIV prevention studies
Diana Nurutdinova1,3*†, Arbi B Abdallah2†, Susan Bradford2†, Catina C O’Leary2† and Linda B Cottler2†

Abstract
Background: Hepatitis C virus (HCV) infection is one of the most frequent chronic blood-borne infections in the
United States. The epidemiology of HCV transmission is not completely understood, particularly in women and
minorities.
Findings: We examined the HCV associated risk factors in substance abusing females involved in National Institute
on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) funded HIV prevention
studies of street recruited women. As a part of the 12 month follow-up, participants were interviewed about
substance use and sexual risk behaviors, including drug implement sharing practices, tattoos, body piercing and
blood transfusions and the sharing of personal hygiene equipment including tweezers, toothbrushes and razors.
Urine and blood testing for HCV antibody (Ab), HIV and sexually transmitted diseases (STDs) was conducted at the
time of assessment.
Among 782 predominantly African American women, 162 (21%) tested positive for HCV Ab. Older age (p < 0.001),
history of injection drug use (p < 0.001), lifetime crack cocaine use (p = 0.004) and having a tattoo (p = 0.01) were
significantly associated with HCV Ab positivity. Other risk factors previously reported in association with HCV Ab
positivity such as sexual risk behaviors were not significantly associated with the presence of a positive HCV Ab.
Conclusions: This large community based sample of predominantly African American substance abusing women
showed high prevalence of HCV Ab positivity and low awareness of their HCV serostatus. Our study demonstrated
that in addition to intravenous drug use (IDU), other factors were significantly associated with HCV Ab positivity
such as having a tattoo and a lifetime history of crack use. Other potential routes of HCV transmission should be
further studied among high risk female populations.

Background
Hepatitis C virus (HCV) infection is one of the most frequent chronic blood-borne infections in the United
States, causing significant morbidity and mortality. An
estimated 4500 in-hospital deaths per year are related to
the HCV infection and associated liver disease in the
United States [1]. Based on the most recent data from
the National Health and Nutrition Examination Survey
III (NHANES III) cohort, the general population prevalence of HCV antibody (Ab) is 1.6% with 1.3% or 3.2
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million persons chronically infected with HCV [2]. Due
to its chronic nature, HCV infection often leads to an
end-stage liver disease that may subsequently require
liver transplantation. HCV infection is the most common indication for liver transplantation in the US;
between 15 and 50% of liver transplantations are performed due to HCV infection [3].
HCV was originally documented as a non-A non-B
virus causing transfusion related hepatitis [4]. HCV is
frequently spread through parenteral exposure and has
been commonly associated with intravenous drug use
(IDU). Introduction of universal blood screening in the
US in 1990 led to a significant decrease in the risk of
transfusion associated HCV infection [5].

© 2011 Nurutdinova et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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The prevalence of HCV infection varies depending on
age, race and certain risk factors. Previous epidemiologic
studies have shown that there is a higher prevalence of
HCV in African Americans, for reasons that are not
clearly identified [6-9]. Prevalence of HCV among
females is lower compared to males regardless of race
[10], though HCV among females has been most extensively studied in the setting of HIV coinfection focused
on the risk of vertical transmission. Among the risk factors associated with the HCV infection, drug injection
remains a predominant route of transmission. Among
IDU’s, HCV prevalence ranges from 60-90% and carries
a high morbidity burden [11].
Sexual transmission of the HCV is possible but much
less efficient as compared to hepatitis B virus or HIV
[12]. The risk of sexual transmission of HCV appears to
be increased in the presence of HIV [13,14]. Vertical
transmission occurs in an estimated 6-7% in the presence of viremia [15]. Routes of transmission other than
IDU have been proposed and include tattoos, body piercings, shared drug preparation equipment and shared
personal hygiene items [16-18]. The prevalence of HCV
infection is higher in non-injection drug users than in
the general public [19,20]; intranasal cocaine use and
sharing of drug-use equipment has been associated with
risk of HCV infection [21]. Additional virologic data
confirming presence of HCV in nasal secretions supports this association [22].
A limited number of epidemiological studies have
comprehensively examined the risk factors associated
with HCV in women, particularly in underrepresented
female populations. We examined HCV associated risk
factors in a sample of substance abusing predominantly
African American females involved in two HIV prevention studies conducted by the Epidemiology and Prevention Research Group (EPRG) at Washington University
School of Medicine.

Methods
Sample and Study Description

The data are derived from the two NIH funded HIV
prevention studies, focused on providing community
based interventions in St Louis, Missouri: Women
Teaching Women (WTW, n = 501), funded by NIDA,
and the NIAAA funded Sister To Sister (STS, n = 348)
conducted between 1998 and 2004.
Women for both studies were recruited by Community Health Outreach Workers (CHOWS) via street outreach [23,24]. The targeted sampling plan identified
areas for recruitment based on the rates of HIV, drug
use and sex trading reported from both community surveillance and law enforcement task force reports. Both
projects were conducted at a satellite office located in
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the outreach area, established in 1989 and sustained
with NIH funding [24,25].
Women were considered eligible if they were 18 years
or older, sexually active in the 12 months prior to entering the study, and did not undergo either alcohol or
substance abuse treatment 30 days prior to the study
enrollment. WTW enrolled women who tested positive
for cocaine, amphetamines or opiates by urine drug
screening and/or had fresh “track marks”, indicative of
current intravenous drug use. STS targeted female heavy
or problem alcohol drinkers who did not test positive
for any substance by urine drug screening. Problem or
heavy alcohol use was determined by a score of four or
greater on the Alcohol Use Disorders Identification Test
(AUDIT), a 10-item questionnaire assessing heavy alcohol consumption [26].
Structured interviews were conducted by trained nonclinician interviewers. The baseline assessments included
a Washington University Risk Behavior Assessment for
Women (WU-RBA-W), Substance Abuse Module
(SAM), and a Diagnostic Interview Schedule (DIS) Version IV [27]. The WU-RBA-W was modeled after the
NIDA Cooperative Agreement RBA that has an established test-retest reliability and validity [28,29]; it was
specifically tailored to assess risky sexual and other
behaviors among women. The SAM is a structured
interview developed as an expanded version of WHO
CIDI [30] that covers substance use, use and dependence on 11 drug categories, alcohol and tobacco [31].
The DIS assessed DSM IV lifetime and current psychiatric disorders (depression, conduct disorder, antisocial
personality disorder, post traumatic stress disorder and
pathological gambling).
In addition to interviews at baseline each woman met
with the Peer Facilitator to receive the NIDA HIV pre
and post-test counseling [32], a blood draw for hepatitis
C antibody (HCV Ab), HIV antibody, Rapid plasma reagin (RPR) syphilis test, and urine testing for Gonorrhea
and Chlamydia. Participants were then randomized into
the intervention groups. In addition to the standard
HIV intervention (HIV pre and post test counseling),
approximately half of the women were assigned to a
Well Woman examination, with and without four peer
delivered sessions. Further details of the intervention in
both STS and WTW have been presented elsewhere
[33].
Participants were followed up at 4- and 12- months post
intervention with repeat assessments including the WURBA-W with a trailer containing additional questions on
sharing drug use equipment, tattoos, body piercings and
blood transfusions, the SAM and DIS. Repeat laboratory
testing for HCV Ab, HIV, RPR, Chlamydia and Gonorrhea
was performed at the 12-month follow-up.
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The data reported in this paper are from the combined STS/WTW sample collected at the 12-month follow-up, as it contained more detailed information on
risk factors traditionally associated with blood-borne
infections such as HCV than the baseline and 4-month
interviews. Participants were consented to join the studies; all procedures were approved by the Washington
University Human Research Protection Office (HRPO,
study numbers 97-0438 and 98-0374), and were compliant with federal Health Insurance Portability and
Accountability Act (HIPAA) regulations; confidentiality
was further assured NIH Certificates of Confidentiality
(NIDA and NIAAA).
Laboratory Testing

Blood samples obtained at the baseline and 12-month
follow-up were tested for HIV, HCV and syphilis. Antibodies to HCV (HCV Ab) were detected with a thirdgeneration enzyme immunoassay (EIA-2.0; Abbott
Laboratories, Abbott Park, IL). Further confirmatory
assay was not performed because HCV Ab testing by
EIA had a high positive predictive value in this high risk
population. HIV testing was conducted with enzyme
immunoassay and confirmed by Western Blot. Blood
samples were also tested for syphilis and urine specimens were collected for chlamydia and gonorrhea
testing.
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of the variables and complex interactions in the models.
SAS® statistical package release 9.1 (SAS Institute, Inc.
1999) was used for bivariate (chi-square) analyses of the
association between the dependent variable of HCV Ab
status and each of the socio-demographic and independent categorical variables. Mean values were compared
using t-tests. All tests were two tailed with a significance
level defined as p < 0.05.

Results
Using street outreach techniques, more than 5500
women in the target recruitment area were approached
by CHOWS about participation in the studies. Further
eligibility screening yielded 935 women; of those, 816
women were interviewed at baseline and 782 presented
for the 12-month follow-up assessments and had HCV
Ab test results available (96% follow-up rate).
At baseline, 173 out of 816 women tested positive for
HCV Ab for a prevalence of 21.2% with similar rate at
the 12-month follow-up (n = 162, 20.7%). However, at
baseline only 70 women (40%) recalled that they were
previously told by a health care provider that they had
had “viral hepatitis”, meaning that the majority of
women were not previously tested and learned about
their positive HCV Ab test for the first time through the
study.
Baseline characteristics

Statistical Analyses

Samples of the STS and WTW studies were combined
for the statistical analyses because women were
recruited in the same high risk areas and during overlapping periods. HIV positive participants were not randomized in either study and were therefore excluded
from the sample (n = 19). Participants who did not
complete all baseline assessments or did not have HCV
Ab results were also excluded from this sample (n =
88), resulting in a total sample of 816 women (STS: n =
348; WTW: n = 501) for baseline and 782 women for
the follow-up. In addition, there were 4 incident HCV
Ab positive test results at follow-up testing that were
excluded from the analysis.
The women were analyzed based on their HCV Ab
status using composite variables with regards to the following categories: demographics, lifetime substance use
and reported risky behaviors. Variables were then tested
for association with HCV Ab positivity using the SAS
ordered logistic regression procedure; odds ratios (OR)
and 95% confidence intervals (CI) were calculated in
four consecutive models. Variables found to be significantly related to HCV Ab positivity in initial model
were included in the next model; each subsequent
model contained variables significant from the previous
model. This approach was chosen to avoid co-linearity

Baseline sociodemographic characteristics of women
recruited in STS/WTW are shown in Table 1, which
shows comparisons according to women’s HCV Ab status. The overall sample was 83% African American
while 77% of the HCV Ab positive women were African
American. Women in HCV Ab positive sample were
significantly different from HCV Ab negative women;
HCV Ab positive women compared to HCV Ab negative
women tended to be older, currently married, less educated and reported history of prior arrests.
Substance Use and Sexual Behaviour

The risk for HCV Ab positivity was associated with substance use and sexual risk behaviors as shown in Table
2. HCV Ab positive women were also more likely to
meet DSM-IV criteria for opiate and alcohol dependence at baseline assessment (26% vs. 51%, p = 0.001
and 52% vs. 61%, p = 0.044 respectively). HCV Ab positive women reported using more drugs than their HCV
negative counterparts; they were more likely to undergo
drug treatment, report binge drinking and attend AA
meetings. The majority of HCV Ab positive women
(69%) reported a history of IDU. HCV Ab positive injectors were more likely to report reusing needles and syringes than HCV Ab negative injectors (p = 0.0293).
There was no significant difference in reusing a cooker,
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Table 1 Sociodemographic characteristics at baseline and follow-up assessments
Characteristics

Baseline
N = 816 (%)

12 Month
N = 782 (%)

12 Month Follow-up
N = 782 (%)
HCV Ab (-)
N = 620

HCV Ab (+)
N = 162

P value

Age
Mean Age, years (±SD)
37 years or older

35.8 ± 9.0
455 (56%)

37.2 ± 9.0
417 (53%)

35.9 ± 8.9
294 (47%)

42.3 ± 7.0
123 (76%)

<0.004
<0.001

Non African American

147 (18%)

132 (17%)

529 (85%)

121 (77%)

0.001

532 (65%)

469 (60%)

394 (63%)

75 (46%)

<0.001

649 (79%)

647 (83%)

507 (82%)

140 (86%)

NS

443 (54%)

415 (53%)

315 (51%)

62 (62%)

0.01

604 (74%)

593 (76%)

448 (72%)

145 (89%)

<0.001

249 (30%)

354 (45%)

291 (47%)

63 (39%)

NS

486 (60%)

576 (74%)

456 (73%)

120 (74%)

NS

Race
Marital status
Never married
Children
More than one child
Education level
Less than high school
education
History of arrest (ever arrested)
Employment status
Did not work in past 12 months
Considered themselves homeless

Table 2 Substance use and risky behaviours reported at follow-up assessment
Characteristics

HCV negative
N = 620 (%)

HCV positive
N = 162 (%)

p value

Reused needles/syringes*

14 (38%)

61 (59%)

0.03

Reused cooker/cotton/rinse water*
Gotten needles from friends/pharmacy*

11 (30%)
30 (81%)

49 (47%)
94 (89%)

NS
NS

Lifetime crack cocaine use

442 (71%)
288 (65%)

152 (94%)
119 (78%)

<0.001
0.003

Substance Use

Reuse straight shooter/crack pipe belonging to othersa
Ever got lesions/burns on lips from smoking cracka
Injection Drug Use

121 (27%)

45 (30%)

NS

41 (7%)

112 (69%)

<0.001

Mean number of drugs used (±SD)

2.1 ± 1.5

3.3 ± 2.2

<0.001

Drug Treatment Program

334 (54%)

125 (77%)

<0.001

More than 7 drinks over past week
Binge drinking

327 (53%)
211 (34%)

93 (57%)
81 (50%)

NS
<0.001

Attended AA meetings

308 (50%)

112 (69%)

<0.001

389 (63%)

103 (64%)

NS
NS

Sexual Behaviors
Past history of STD
Sexual History in Past 4 mo
Mean number of sex partners (±SD)

3.4 ± 9.8

4.5 ± 12.3

Always used condom

116 (19%)

29 (18%)

NS

Sex under influence of alcohol/drugs
Traded sex for drugs, money and other things

466 (75%)
274 (44%)

121 (75%)
104 (64%)

NS
<0.001

Potential Risk Factors
Number of times shared tweezers/nail clippers (±SD)

21.1 ± 36.0

24.6 ± 37.9

NS

Number of times used toothbrush of other person (±SD)

1.21 ± 7.41

0.8 ± 2.8

NS

Ever gotten a tattoo

154 (25%)

56 (35%)

0.01

Ever gotten a body piercing

569 (92%)

152 (94%)

NS

Ever received a blood transfusion

106 (17%)

54 (33%)

<0.001

HCV: Hepatitis C Virus: STD, Sexually Transmitted Diseases: AA, Alcoholics Anonymous.
* Among IDU only, a Among crack cocaine users only.
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cotton or rinse water or in obtaining needles from
friends and or a pharmacy. HCV Ab positive women
were more likely to smoke crack cocaine than HCV Ab
negative women (94% vs. 71%, p < 0.001). Among
cocaine users, HCV Ab positive women were more
likely to reuse crack cocaine related equipment compared to HCV Ab negative women.
Women recruited in these studies were sexually active
with a mean of 3 - 4 sex partners in the preceding 4
months. Despite reporting several new sex partners in
the past 4 months, condom use was low (19%) regardless of HCV Ab status. Both groups reported frequent
use of alcohol or drugs before or during their sexual
encounters; HCV Ab positive women compared to HCV
Ab negative women were more likely to be involved in
trading sex for drugs, money and other things. More
than 60% of women in both groups reported history of
a sexually transmitted disease.
Among other risk factors commonly associated with
blood borne infections, both having a tattoo and having had a blood transfusion were found to be significantly associated with HCV Ab positivity in the
bivariate analysis. No differences were observed in relationship to body piercings or sharing of personal
hygiene equipment.

Multivariate Analyses

Multivariate logistic regression was performed to identify factors associated with HCV Ab positivity controlling for risk factors associated with HCV transmission
in four stages (Table 3). In the first stage, when sociodemographic variables were entered, only older age and
history of arrest significantly predicted HCV Ab. Race
(African American) and more education were significantly protective of HCV Ab status. In the second stage
model, substance use and treatment variables were
added to the significant variables from the first stage. In
this model, older age remained significant. Additionally,
IDU was strongly associated with HCV Ab, with injectors being over 26 times more likely to be HCV Ab
positive than non-injectors. The third stage model,
which added sexual behaviors, revealed that older
women who had history of injection drug use and
traded sex were more likely to be HCV Ab positive. In
the final stage model, having a tattoo and reporting lifetime crack cocaine use, in addition to age and history of
IDU remained significantly associated with HCV Ab
positivity. History of blood transfusions displayed a positive trend in association with HCV Ab positivity, but did
not reach statistical significance. Overall, IDU remained
the strongest predictor.

Table 3 Odds ratios for HCV Ab positivity
Model 1
Variables

OR

95% CI

Never Married

0.80

0.54, 1.20

Have >1 kids

0.81

0.46, 1.41

Worked in past 12 months
Considered being homeless

0.82
1.07

0.56, 1.19
0.70, 1.63

African American

0.35

Older (37+ years)

3.81

High school education and more
Ever been arrested

Model 2
OR

95% CI

0.21, 0.56

1.27

0.66, 2.47

2.43, 5.98

2.96

1.78, 4.92

0.60

0.41, 0.88

0.78

0.49, 1.26

2.69

1.53, 4.72

Model 3

Model 4

OR

95% CI

OR

95% CI

2.78

1.68, 4.59

3.04

1.74, 5.31

30.73

18.70, 50.50

23.26

14.31, 37.80

Previous history of STD

0.89

0.54, 1.49

Sex under influence

0.71

0.40, 1.27

Number of sex partners in past 4 months

0.99

0.97, 1.01

Always used condom in past 4 months

1.34

0.73, 2.46

Trading sex

1.76

1.06, 2.93

1.33

0.67, 2.63

Binge drinking

1.19

0.73, 1.93

Number of drugs

1.02

0.89, 1.18

Drug treatment
IDU

1.22
26.17

0.66, 2.26
15.19, 45.08

Attended AA meetings

1.16

0.65, 2.05

1.22

0.75, 2.00

Ever gotten a tattoo
Lifetime crack cocaine use

2.05
3.87

1.15, 3.66
1.66, 9.01

Ever received blood transfusion

1.67

0.99, 2.82

OR: Odds ratio, CI: confidence interval, IDU: Injecting drug users, STD: Sexually Transmitted Disease
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Subgroup analyses

In further subgroup analyses, HCV Ab positive women
were stratified by injection drug use status: 50 HCV Ab
positive women reported no prior IDU and 111 HCV
Ab positive women reported lifetime IDU. HCV Ab
positive IDU’s were more likely to have a tattoo and
reported more crack cocaine use (40% vs. 24%, p = 0.05
and 98% vs. 86%, p = 0.002 respectively). When a subgroup of non-injectors was analyzed by their HCV Ab
status, the prior history of blood transfusion, lifetime
crack cocaine use and trading sex were predictors of
HCV Ab positivity status (Table 4).

Discussion
Compared to the general population, a substantially
higher prevalence of HCV Ab positivity in this large
community based sample of predominately African
American substance abusing females was a key finding.
Nearly two thirds of women with HCV antibodies were
not aware of their viral hepatitis status; this is particularly concerning given the chronic nature of HCV infection and implies lack of awareness among health care
providers and existing barriers to HCV screening in this
population.
Past or present injection drug use in these studies was
strongly associated with HCV Ab positivity as shown in
previous reports [18,34,35]. Although among the HCV
Ab positive subjects almost 70% had a history of IDU,
30% reported no IDU despite several questions on injection drug use in three different portions of the structured assessments.
In addition to injection drug use, having a tattoo and
history of crack cocaine use were independently associated with HCV Ab positivity after controlling for IDU.
Both crack cocaine use and tattoos have been identified
as independent risk factors for HCV acquisition in previous reports, especially non-injection drug implement
sharing practices [17,20,21,36,37]; however, urban folklore also indicates that a tattoo is a proxy marker for
injection drug use and other risk factors. Our study did
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not assess further details regarding the type or design,
or where the tattoos were received; although some
reports suggest these factors may play a role in HCV
acquisition [38,39].
In a subgroup analysis of this community sample of
non-injecting HCV Ab positive females, a number of
high risk behaviors (high prevalence of crack cocaine
use accompanied by drug implement sharing) as well as
high risk sexual behaviors (sex under influence and trading sex) was significantly higher among the HCV Ab
positive IDU’s As noted, these risky behaviors have been
associated HCV Ab positivity in non-injecting populations [40-42].
There is mounting evidence regarding the increased
risk of HCV among non-IDU’s suggesting routes of
administration and drug implement sharing practices
may serve as an alternative HCV transmission pathway
[41]. Data regarding the risk of HCV transmission
remains conflicting mainly due to limited amounts of
research specifically devoted to these HCV associated
risks in non-IDU populations and small sample sizes.
Since non-injection cocaine related risk was originally
reported by C. Conry-Cantilena, et al. [18] and attributed to sharing straws while using cocaine intranasally, it
has been a subject of discussion [43]. Some investigators
were not able to confirm the independent association of
intranasal cocaine use and risk of hepatitis C, although
their findings highlight other potential iatrogenic
sources of the infection [44,45]. Several studies have
shown higher rates of HCV Ab positivity in non-injection drug users although subject recruitment may have
introduced a selection bias. For example, a study by
Koblin et al. [19] aimed to recruit non-injection drug
users, including non-injection heroin users, who could
have been former injection drug users [36]. Rosenblum
et al. [46] examined a non IDU population based on
having a history of less than 5 lifetime injection episodes, although it is evident that even a single injection
exposure could theoretically be sufficient for HCV transmission. Studies by Tortu and colleagues [20,21] that

Table 4 Subgroup analyses of risk factors among non-injectors
Reported Behaviors among Non-injectors

HCV Ab neg
N = 578

HCV Ab pos
N = 50

P value

Ever received a blood transfusion

95 (16%)

15 (30%)

0.02

Ever gotten a tattoo

138 (23%)

12 (24%)

NS

Reused crack pipe belonging to others

262 (64%)

31 (72%)

NS

Ever got lesions/burns on lips from smoking cracka

104 (25%)

9 (21%)

NS

Lifetime crack cocaine use
Sex under influence of alcohol/drugs

411 (71%)
430 (74%)

43 (86%)
34 (68%)

0.02
NS

Traded sex for drugs, money and other things

249 (43%)

29 (58%)

0.04

Snorted cocaine

102 (18%)

10 (20%)

NS

a

HCV: Hepatitis C Virus; Among crack cocaine users only
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validated self reported drug use, with methodology similar to that utilized in the STS/WTW studies, found high
rates of HCV among self reported non-injection drug
users. Extensive data obtained on drug implement sharing practices suggested that such practices might be a
risk factor for HCV transmission [21]. Furthermore,
Tortu et al. have suggested that intranasal cocaine use
could serve as an indirect determinant for other substance use practices leading to HCV transmission, like
injection drug use or injection practices that are not
typically perceived as IDU (such as skin popping) [20].
Other potential routes of transmission among women
in our study, such as tattooing, were significantly associated with HCV Ab status. Non commercial tattooing
has been implicated as a significant risk factor in HCV
transmission and deserves more detailed prospective
investigation [47]. Similarly to other investigators, we
did not find an association with hygiene measures, such
as sharing toothbrushes or nail clippers, suggested as
potential HCV transmission risk factors [17,48].
In our study HCV Ab positivity was not strongly associated with high risk sexual behaviors. Other studies
have found that sexual transmission of HCV is associated with high risk sexual practices, including having
an IDU sexual partner. To date, the role of sexual behaviors as a risk factor for HCV transmission remains controversial mainly due to the complex determination of
the magnitude of the transmission risk which may vary
significantly depending on a specific population being
studied [49,13,38]. Besides, studies examining HCV
transmission seem to frequently involve HIV co-infected
women that appear to have a higher HCV Ab prevalence independent of other risk factors [38].
Although our study was not designed specifically for
exploring the epidemiology of hepatitis C, it focused on
the risk factors associated with HIV that share common
routes of transmission with HCV. As a result, these data
provided us with very detailed information concerning
potential risk factors associated with the transmission of
HCV. One of the limitations of this paper is that the
data is cross-sectional and, as a result, we are unable to
establish the timing of the HCV infection. These two
studies were not specifically designed to examine the
epidemiology of HCV infection but rather to determine
a baseline prevalence of blood-borne infections and to
evaluate the HIV intervention techniques.
Another shortcoming of the study design is that a single ELISA testing for HCV infection was utilized.
Despite a high HCV risk profile in this population, a
small fraction of false positive ELISA results is possible,
although this possibility is unlikely to significantly affect
the results of our analyses.
Self-reported drug use is another shortcoming of this
study which could result in underestimated contribution
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of IDU to the risk of HCV infection in this population.
In order to avoid that, participants were asked about
injection drug use several times during the course of the
interview and examined for the presence of injection
track marks. Majority of studies evaluating epidemiological risk factors have to utilize self-reported measures,
the reliability of which have been studied. The two studies primarily targeted hard to reach populations, which
are traditionally challenging to recruit and therefore
rarely evaluated in a clinical research setting; as a result
some respondents were not located or opted to not participate in either of the studies. Nevertheless we feel
that the large sample of respondents recruited is representative of the targeted population.

Conclusions
This study highlights the prevalence of risk factors common for several major blood borne infections in at risk
difficult to reach female populations that is commonly
understudied and underreported in literature. Our findings strongly support previous epidemiologic studies
showing that injection drug use is a major factor contributing to HCV Ab positivity in this large community
sample of predominantly African American substance
abusing women. Another revealing finding was lack of
awareness of HCV Ab status among the study participants. The fact that the majority of women were not
aware of their HCV Ab status has significant implications both from the clinical and public health perspective. Programs targeting high risk female populations are
needed in order to improve HCV testing and counseling, develop strategies overcoming barriers to care and
ensure referrals to comprehensive treatment models that
incorporate addressing substance use. Interestingly, our
study demonstrated that factors other than IDU were
significantly associated with HCV Ab positivity such as
having a tattoo and a lifetime history of crack use without injection use. Other potential routes of HCV transmission should be further investigated in large-scale
prospective studies particularly among high risk female
populations.
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